Stereospecific binding of the antidepressant rolipram to brain protein structures

European Journal of Pharmacology

Volumn 127, Issue 1-2, 1986, Pages 105-115

  Schneider, Herbert H ^a   Schmiechen, Ralph ^a   Brezinski, Marina ^a   Seidler, Jörg ^a  

^a Research Laboratories of Schering AG Berlin ^*

Author keywords

Antidepresant; Binding sites; Brain structures; Phosphodiesterase inhibitor; Rolipram; Stereospecify

Indexed keywords

2 AMINO 4,5 DIHYDRO 6 METHYL 5 OXO 4 PROPYL 1,2,4 TRIAZOLO[1,5 A]PYRIMIDINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIDEPRESSANT AGENT; RADIOISOTOPE; ROLIPRAM;

ANIMAL CELL; BINDING SITE; BRAIN; CAT; CENTRAL NERVOUS SYSTEM; DRUG BINDING; DRUG COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; GERBIL; GUINEA PIG; HAMSTER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ROLIPRAM H 3; STEREOSPECIFICITY; TOPICAL DRUG ADMINISTRATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMAL; ANTIDEPRESSIVE AGENTS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CATIONS; CATS; GUINEA PIGS; HAMSTERS; IN VITRO; KINETICS; MICE; NERVE TISSUE PROTEINS; ORGAN SPECIFICITY; PYRROLIDINONES; RABBITS; RATS; RECEPTORS, NEUROTRANSMITTER; ROLIPRAM; SPECIES SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 0022459284     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(86)90210-4     Document Type: Article

References (33)

1. Cyclic nucleotide phosophodiesterases Properties activators inhibitors structure-activity relations and possible role in drug development
2. Cyclic nucleotide phosphodiesterases
3. Neurotransmitter, hormone, or drug receptor binding methods
4. Chromatographische Racemattrennung
5. Anomalous equilibrium binding properties of high-affinity racemic radioligands
6. Properties of cyclic nucleotide phosphodiesterase from rat brain
7. Regional cyclic nucleotide phosphodiesterase activity in cat central nervous system: Effects of benzodiazepines
8. Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxy cyclic AMP and potassium ions
9. Comparative thermodynamics of benzodiazepine receptor ligand interactions in rat neuronal membranes
10. On the mechanism of relaxation of tracheal muscle by theophylline and other cyclic nucleotide phosphodiesterase inhibitors
11. 2+ in intact frog skeletal muscle
12. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain
13. Rolipram as an anti-depressant
14. Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases. Relationship to pharmacological activity
15. Effect of IBMX and rolipram on histamine stimulated cAMP accumulation in guinea-pig hippocampal slices
16. Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotropic compound rolipram
17. Brain cAMP and memory in mice
18. 3H]-para-Aminoclonidine: A novel ligand which binds with high affinity to α-adrenergic receptors
19. Inhibition of lung cyclic AMP- and cyclic GMP-phosphodiesterases by flavonoids and other chromone-like compounds
20. Brain response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation
21. Rolipram stereoselectively down-regulates β-adrenergic receptors in rat cerebral cortex
22. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): A potent inhibitor of adenosine cyclic 3′, 5′-mono-phosphate phosphodiesterases in homogenates and tissue slices from rat brain
23. 6-phenylisopropyla-denosine
24. 1-Isoamyl-3-isobutylxanthine: A remarkably potent agent for the potentiation of norepinephrine, histamine, and adenosine-elicited accumulations of cyclic AMP in brain slices
25. Molecular aspects of neurotransmitter receptors: An overview
26. Effect of different phosphodiesterase (PDE) inhibitors and cyclic nucleotides on motor behaviour and body temperature in rats
27. Selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors - a novel class of anti-depressants?
28. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors
29. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors
30. Species differences in behavioural effects of rolipram and other adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors
31. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo
32. Induction of a characteristic behavioural syndrome in rats by rolipram and other selective adenosine cyclic 3′,5′-monophosphate (cAMP) phosphodiesterase (PDE) inhibitors
33. Fundamental difference between the molecular interactions of agonists and antagonists with the β-adrenergic receptor